The successful colonization of the majority of the population by human cytomegalovirus is a direct result of the virus's ability to establish and, more specifically, reactivate from latency. The underlying cellular factors involved in viral reactivation remain unknown. Here, we show that the host complex facilitates chromatin transcription (FACT) binds to the major immediate early promoter (MIEP) and that inhibition of this complex reduces MIEP transactivation, thus inhibiting viral reactivation.
H uman cytomegalovirus (HCMV) infection is lifelong and in healthy individuals remains asymptomatic, residing latently in CD34
ϩ hematopoietic progenitor cells (HPCs) (1) (2) (3) (4) . Reactivation from latency is an intricate event, dictated by both host and viral components, and causes a variety of symptoms in immunocompromised individuals (reviewed in reference 5). Here, we show that HCMV utilizes the facilitates chromatin transcription (FACT) complex to aid in transactivation of the major immediate early promoter (MIEP) following quiescence. FACT, a heterodimer of suppressor of Ty16 (SPT16) and structure-specific recognition protein 1 (SSRP1) (6) , is highly enriched in HPCs (7) . This complex repositions histones, rendering nucleosome-containing DNA accessible to RNA polymerase II. We report that inhibition of FACT suppresses MIEP transcription.
The MIEP drives expression of the IE genes UL122 and UL123, viral transactivators that facilitate lytic replication. This promoter is repressed during HPC latency, thus restricting viral replication (8, 9) . Using our Kasumi-3 (K3) HPC latency model system, we reported that phorbol ester (e.g., tetradecanoyl phorbol acetate [TPA]) treatment following latent infection stimulates MIEP-driven transcription and the production of infectious virus (10) . Also, tumor necrosis factor alpha (TNF-␣) or interleukin-1␤ (IL-1␤) treatment of latently infected K3 cells (K3s) (10) or primary HPCs induced MIEP transcription (8, 11) . These inflammatory cytokines, as well as TPA, activate NF-B (12, 13) . As the MIEP contains four NF-B binding sites (14-16), we hypothesized that one could block MIEP activation following TPA or TNF-␣ treatment of quiescently infected K3s by treatment with quinacrine, which indirectly targets a subset of NF-B-responsive promoters and activates p53 through direct inhibition of FACT (17) . Indeed, quinacrine treatment inhibits TPA-or TNF-␣-induced activation of the MIEP in quiescent K3s (Fig. 1) , suggesting that quinacrine treatment inhibits viral MIEP transactivation.
In order to ensure that quinacrine's impact on MIEP-driven transcription was not due to pleotropic effects beyond targeting FACT, we utilized three different curaxins, compounds that bind to and tether FACT to DNA (17) . We first asked if curaxins could inhibit lytic replication by pretreating permissive fibroblasts, which express FACT ( Fig. 2A) , with three different curaxin compounds or vehicle before infecting the cells with TB40/E-mCherryUL99eGFP. This bacterial artificial chromosome (BAC)-derived clinical isolate has the simian virus 40 (SV40) promoter driving mCherry expression (18) and enhanced green fluorescent protein (eGFP) fused to the C terminus of UL99 encoding the true late protein, pp28. Surprisingly, curaxin treatment impacted MIEP transcription within 6 h postinfection (hpi) (Fig. 2B) , suggesting that at least in fibroblasts, FACT transcriptional regulation may be important. Additionally, all three curaxin compounds significantly decreased lytic infection, as demonstrated by the reduction of mCherry-positive cells. Additionally, eGFP expression in the mCherry-positive cells is reduced in the curaxin-treated infected cells (Fig. 2C) , as is UL123 mRNA expression at 96 hpi under both high-and low-serum conditions (Fig. 2D) , suggesting that these compounds impact lytic replication prior to viral late gene transcription. Importantly, at the concentrations used, none of the curaxins impacted cell viability (Fig. 2E) .
We next assessed the ability of curaxins to block MIEP-driven transcription following stimulation of quiescent/latent infections. We quiescently infected K3s with TB40/E-mCherry and then added curaxins or vehicle prior to stimulation with or without by immunoblotting with an antibody specific for SPT16 (Santa Cruz Biotechnology). Cellular tubulin is shown as a control (Sigma-Aldrich). (B) Human foreskin fibroblasts were treated with 1 M CBLC000, 10 nM CBLC100, 100 nM CBLC137, or vehicle (dimethyl sulfoxide [DMSO]) for 2 h prior to infection with TB40/E-mCherry-UL99eGFP (multiplicity of infection, 0.1). Total RNA was collected at 6 hpi, and UL123 transcripts were measured by reverse transcriptase quantitative PCR using protocols previously described (10) . UL123 expression is shown relative to cellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH). All samples were analyzed in triplicate. (C) Human foreskin fibroblasts were infected as described for panel B and monitored for mCherry expression as a measure of lytic infection as well as pUL99eGFP expression, which denotes successful DNA replication and late-stage protein translation. Representative images were collected at 96 h postinfection. (D) Human foreskin fibroblasts were grown to confluence and then cultured in either 10% or 0.5% serum-containing medium. Cells were then pretreated with the compounds and infected as described for panel B. Total RNA was analyzed at 96 hpi for UL123 expression relative to cellular glyceraldehyde-3-phosphate dehydrogenase. Samples were analyzed in triplicate. (E) Equal numbers of human foreskin fibroblasts were cultured in the respective serum-containing medium for 24 h prior to the addition of drug compounds. Cell viability was quantified by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay at 48 h posttreatment according to the manufacturer's protocol (Promega; CellTiter 96 Aqueous One Solution cell proliferation assay). AU, arbitrary units; FBS, fetal bovine serum.
TNF-␣. Quiescently infected cultures pretreated with vehicle and then TNF-␣ demonstrated activation of UL123 transcription compared to parallel cultures lacking additional stimuli (Fig. 3A) . However, curaxin pretreatment was sufficient to suppress MIEP transcription in the presence of TNF-␣, as UL123 mRNA expression was not significantly upregulated upon cytokine addition. Although K3s are a suitable in vitro latency model system with which to interrogate HCMV, it is nonetheless critical to confirm salient findings, when possible, in ex vivo systems that utilize primary HPCs. We latently infected cord blood-derived ex vivo-cultured CD34
ϩ HPCs with TB40/E-mCherry. We treated these cells with either CBLC100 or vehicle upon culturing them in reactivation medium (19) . As expected, UL123 expression was suppressed in latently infected primary CD34
ϩ HPCs, regardless of treatment (Fig. 3B) , and yet was increased in the vehicletreated infected cells cultured in reactivation medium. However, this increase was blocked in the presence of CBLC100 (Fig. 3B) . Importantly, none of the curaxins impacted HPC viability (Fig. 3C) . Together, these data indicate that the curaxin compounds successfully suppress HCMV lytic replication in fibroblasts and MIEP-dependent transcription following stimulation of in vitro quiescently infected K3s or ex vivolatently infected primary HPCs following reactivation.
We next hypothesized that FACT's presence on the MIEP is a requirement for transcription. To determine if FACT functions directly on the MIEP as opposed to exerting its effects epistatically, we monitored SPT16 levels and found that while its expression is high in K3s, total SPT16 decreases as these cells differentiate (Fig.  4A) , confirming previous findings in other cell types (7). We next assessed the presence of FACT on the MIEP by chromatin immunoprecipitation (ChIP). FACT is enriched on the MIEP relative to a nonpromoter region of the virus, UL69, prior to and during stimulation of infected K3s (Fig. 4B) . This is not surprising, as FACT binds to DNA in the presence or absence of active transcription (17, 20) . Thus, to determine if FACT functions to aid MIEP transactivation, we transduced K3s with lentiviral constructs expressing either a nonspecific or a validated SPT16-specific short hairpin RNA (shRNA). SPT16 knockdown reduced SPT16 expression (Fig. 4C ) without affecting cell viability (Fig. 4D) . TNF-␣ treatment of these cells following quiescent infection resulted in significantly reduced UL123 transcripts compared to similarly treated infected K3s transduced with nonspecific shRNA (Fig. 4E) . Thus, although FACT is present at the MIEP under both quiescent and transactivated conditions, this complex is critical in facilitating transcription from this promoter upon treatment with the appropriate transactivation stimulus.
Our findings demonstrate that HCMV evolved to utilize the FACT complex to aid in successfully activating the MIEP. MIEP transactivation following latency is the "switch" that allows the virus to subsequently enter the lytic replicative cycle, and it is evident that these processes are multifaceted and likely quite complicated events. We propose that FACT's presence on the MIEP aids in transactivation of this promoter when conditions favor reactivation (i.e., inflammatory cytokine influx), which is limited by curaxins, thereby suppressing MIEP transcription. Curaxins may represent novel therapeutics that could dampen HCMV reactivation, posing a significant advancement in clinical treatment of HCMV, whose current therapies target lytic replication where disease is primed to occur. with TB40/E-mCherry (multiplicity of infection, 1.0) for 18 days under quiescent conditions. The infections were then treated with 1 M CBLC000, 10 nM CBLC100, or 100 nM CBLC137, concentrations previously determined to have no effect on cell viability, or vehicle (dimethyl sulfoxide [DMSO]) for 2 h prior to treatment with 20 ng/ml TNF-␣ or no treatment for an additional 2 days. (B) Immunopurified primary CD34 ϩ HPCs isolated from pooled patient deidentified cord blood collections (19) were infected with TB40/E-mCherry (multiplicity of infection, 2) under latency conditions for 10 days. The infected cells were then treated with 10 nM CBLC100 or vehicle (dimethyl sulfoxide) for 2 h prior to an additional 2 days in medium favoring reactivation or latency conditions. For both panels A and B, cells were harvested and UL123 mRNA was analyzed by reverse transcriptase quantitative PCR. All samples were assessed in triplicate and normalized to the cellular transcript, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). AU, arbitrary units; NT, not treated. (C) An equal number of K3s were cultured for 24 h and then treated with the respective compounds as in panel A for 48 h, after which cell viability was quantified by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay as in Fig. 2E .
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